52 results about "Locally advanced" patented technology

The present invention relates to a novel system for predicting a prognosis capable of predicting the prognosis of locally advanced gastric cancer, and more specifically, capable of predicting a clinical result after a resection during gastric cancer surgery through gene set enrichment comparative analysis.

Provided herein are methods of treating, preventing and / or managing locally advanced breast cancer, including inflammatory breast cancer, which comprise administering to a patient one or more immunomodulatory compounds or enantiomers or mixtures of enantiomers thereof, or pharmaceutically acceptable salts, solvates, hydrates, co-crystals, clathrates, or polymorphs thereof.

A catheter system adapted for navigating, guiding and implanting a catheter or a plurality of catheters in a spatially-defined implantation within the tissue of a patient is provided. The system can include a tissue navigation system and a probe to inform the navigation system to guide emplacement of the catheters within a target tissue. The probe can provide images, such as fiberoptic visual images, or ultrasound images, or can provide radiolocation data, to guide the catheter emplacement. The catheters supply a pressurized liquid including a bioactive agent, such as can be used in the treatment of cancer, for example 123I- or 125I-IUDR. The system and methods provided can be used in the treatment of locally advanced tumors, such as cancers of the brain, head or neck, esophagus, prostate, ovary, liver, pancreas, bladder or rectum.

The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof.

The invention relates to a fibrin glue composite system loaded with cisplatin. and specifically provides a fibrin glue, which is prepared from thrombin solution and fibrinogen solution as raw materials. The invention also provides a cisplatin / fibrin glue composite system which is prepared by taking a cisplatin solution, a thrombin solution and a fibrinogen solution as raw materials. The cisplatin / fibrin glue composite system has an excellent inhibition effect on postoperative growth of breast cancer, and has a good application prospect in preparation of drugs for treating tumors. More importantly, the cisplatin / fibrin glue composite system is combined with radiotherapy to play a synergistic interaction role in inhibiting recurrence of locally advanced breast cancer, and can more effectively inhibit recurrence of locally advanced breast cancer. Therefore, combined use of the fibrin glue composite system loaded with cisplatin with a radiotherapy device has broad application prospects inpreparing combined treatment equipment for treating tumors (especially locally advanced tumors).

The present invention relates to a method for determining or predicting the response of a patient diagnosed with locally advanced rectal cancer to chemoradiotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with rectal cancer to specific medicaments, radiotherapy and / or chemotherapy. More specifically, the present invention provides methods which measure kinase activity by studying phosphorylation levels and profiles in samples of said patients.

The present disclosure is directed to methods of treating malignant melanoma by irradiating sites to which melanoma cells have become locally advanced, surgically undesirable, or have metastasized. In various embodiments of the invention, patients are treated with radiation doses in amounts ranging from about 25 to 230 cGy, preferably about 100 cGy to about 200 cGy, at least twice a day. The treatment regimen can be performed in the absence of additional treatments for the metastatic melanoma (e.g., chemotherapy / targeted therapy / immunotherapy) or in combination with additional therapies for chemotherapy / targeted therapy / immunotherapy. Various additional embodiments relate to the administration of between 20 and 100 fractions of radiation, preferably between 20 and 56 fractions of radiation.